Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has shared an announcement.
On October 31, 2025, NeOnc Technologies Holdings, Inc. announced significant leadership changes with Dr. Thomas Chen resigning as CEO to focus on his roles as Chief Medical Officer and Chief Scientific Officer. Amir Heshmatpour was appointed as the new CEO, effective immediately, while continuing his roles as President and Executive Chairman. This leadership transition is part of NeOnc’s strategy to advance its clinical trials and capitalize on Heshmatpour’s expertise in corporate strategy and business development, aiming to drive the company’s next phase of growth and innovation in CNS cancer therapies.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics. The company is pioneering therapies for CNS cancers and is advancing its NEO™ drug development platform, which includes NEO100™ and NEO212™ therapeutics currently in Phase II clinical trials.
Average Trading Volume: 76,717
Technical Sentiment Signal: Strong Buy
Current Market Cap: $201M
For an in-depth examination of NTHI stock, go to TipRanks’ Overview page.